NCT confers the highest advantages in HER2 positive and TN breast cancer patients, for whom pCR can be obtained in 50–60% [7,8,9] of cases, while the inherent rates are lower in luminal cancer, where pCR is achieved on average in 10–20% of patients [6,7,8,9]. This evidence concerns the gene ERBB2 and breast carcinoma.